宜明昂科-B(01541.HK)與Axion Bio合作再獲500萬美元付款,累計收款2000萬美元
格隆匯5月7日丨宜明昂科-B(01541.HK)發佈公告,有關公司與Axion Bio, Inc.(“Axion Bio”,前稱SynBioTx Inc.)於2024年8月1日訂立授權及合作協議及根據授權及合作協議收取付款。公司根據授權及合作協議已自Axion Bio收取500萬美元的第二筆近期付款。截至本公告日期,根據授權及合作協議,公司已收取首付款及近期付款合共2000萬美元,標誌着與Axion Bio合作的重要里程碑,併爲進一步發展奠定了堅實基礎。根據授權及合作協議,公司預計未來將收取不超過3000萬美元的餘下潛在近期付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.